Pgc 1Α Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PGC-1α (PPARGC1A / Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha) is a transcriptional coactivator protein that serves as the master regulator of mitochondrial biogenesis and cellular energy metabolism.
| Property |
Value |
| Protein Name |
PGC-1α |
| Gene Symbol |
PPARGC1A |
| UniProt ID |
Q9UBX2 |
| Molecular Weight |
91 kDa |
| Subcellular Localization |
Nucleus, Cytoplasm |
| Protein Family |
PPARGC1 family |
| Tissue Distribution |
High in tissues with high metabolic demand: brain, heart, skeletal muscle, brown adipose tissue |
PGC-1α is a versatile transcriptional coactivator with multiple functional domains:
- N-terminal Activation Domain: Transactivation domain containing multiple LXXLL motifs for nuclear receptor binding
- RS-rich Domain: Regulatory domain with multiple serine-arginine repeats
- C-terminal Domain: Contains RNA recognition motif (RRM) and binding domains for transcription factors
| Modification |
Effect |
| Acetylation (SIRT1) |
Activates PGC-1α |
| Phosphorylation (AMPK, p38 MAPK) |
Activates PGC-1α |
| Methylation (PRMT1) |
Activates PGC-1α |
| Ubiquitination |
Targets for degradation |
PGC-1α regulates gene expression by interacting with:
- Nuclear Receptors: PPARs, ERRs, RORs, thyroid hormone receptors
- Transcription Factors: NRF-1, NRF-2, YY1, MEF2
- Chromatin Remodelers: SRC-1, p300/CBP
PGC-1α activates genes involved in:
- Mitochondrial DNA replication (TFAM, TFB2M)
- Electron transport chain complexes
- Fatty acid oxidation enzymes
- ATP synthesis
- Gluconeogenesis: Activates hepatic glucose production
- Fatty Acid Oxidation: Upregulates β-oxidation genes
- Thermogenesis: Controls brown adipose tissue function
- Reduced PGC-1α expression in AD brain
- Mitochondrial dysfunction in neurons
- Therapeutic target: PGC-1α activators improve cognition in models
- Protects dopaminergic neurons
- Mitochondrial complex I deficiency in PD
- LRRK2 regulates PGC-1α activity
- Mutant huntingtin disrupts PGC-1α function
- Mitochondrial dysfunction in HD
- Restoring PGC-1α improves phenotypes
- Type 2 Diabetes: Insulin resistance
- Obesity: Reduced energy expenditure
| Compound |
Status |
Mechanism |
| AICAR |
Research |
AMPK activation |
| Resveratrol |
Dietary supplement |
SIRT1-mediated activation |
| Bezafibrate |
FDA approved |
PPAR activation |
| Metformin |
FDA approved |
AMPK activation |
| Exercise |
Clinical |
Physiological inducer |
- AAV-mediated PPARGC1A delivery
- SIRT1 activators (NAD+ boosters)
- Lin J, et al. (2004) Transcriptional co-activator PGC-1 alpha drives mitochondrial biogenesis. Nature. PMID: 15192144
- Wareski P, et al. (2009) PGC-1alpha regulates mitochondrial density in neurons. J Biol Chem. PMID: 19211836
- St-Pierre J, et al. (2006) Suppression of ROS and neurodegeneration by PGC-1alpha. Cell. PMID: 16547501
The study of Pgc 1Α Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lin J, Handschin C, Spiegelman BM. Metabolic control through the PGC-1 family of transcriptional coactivators. Cell Metab. 2005;1(6):361-370. PMID:16011085
- Wareski P, et al. PGC-1alpha and PGC-1beta regulate mitochondrial density in neurons. J Biol Chem. 2009;284(32):21379-21385. PMID:19211836
- St-Pierre J, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397-408. PMID:16547501
- Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators. Physiol Rev. 2007;87(2):507-538. PMID:17499144
- Valsecchi F, et al. PGC-1alpha in disease settings. Cell Death Differ. 2014;21(1):58-66. PMID:24270406